Dermatology Times

OCTOBER 26, 2024

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

Innovations 36

Innovations Tools Clinic 36

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. “These findings indicate that upadacitinib may address an unmet medical need in patients with moderate-to-severe AD who do not achieve an adequate response while taking dupilumab,” conclude researchers who were led by Christopher Bunick, MD, PhD, an Associate Professor of Dermatology

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

Dermatology Times

OCTOBER 26, 2024

The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.

Eczema 36

Eczema 36

Dermatology Times

OCTOBER 26, 2024

During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic and eczema and early career controversies.

Eczema 36

Eczema Clinic Dermatology 36

Dermatology Times

OCTOBER 26, 2024

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Management 36

Management Clinic 36

Dermatology Times

OCTOBER 26, 2024

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Clinic 36

Clinic 36

Dermatology Times

OCTOBER 26, 2024

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Safety 36

Safety Dermatitis 36

Dermatology Times

OCTOBER 26, 2024

A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.

Dermatitis 36

Dermatitis Clinic 36